Enabling Targeted Delivery with Drug Conjugates: ADCs, RLTs and Beyond

Targeted drug conjugates are redefining precision medicine, offering the potential to deliver potent therapies directly to diseased cells while minimizing off-target toxicity. This panel will dive into the latest advancements in antibody-drug conjugates (ADCs), radioligand therapies (RLTs), and emerging conjugate platforms. Experts will discuss linker technologies, payload selection, delivery challenges, formulation considerations and strategies to optimize safety and efficacy.